Current therapeutic approaches to target T2D include dipeptidyl peptidase-IV (DPP-IV) inhibitors5, glucagon-like peptide-1 (GLP-1) agonists6, and α-glucosidase inhibitors7. Here, DPP4 is linked to type 2 diabetes mellitus.